TY - JOUR
T1 - Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
AU - Cormican, M. G.
AU - Jones, R. N.
PY - 1997
Y1 - 1997
N2 - Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, sparfloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 μg/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 μg/ml). It has limited activity against gram- negative anaerobes.
AB - Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, sparfloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 μg/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 μg/ml). It has limited activity against gram- negative anaerobes.
UR - https://www.scopus.com/pages/publications/0031026256
U2 - 10.1128/aac.41.1.204
DO - 10.1128/aac.41.1.204
M3 - Article
C2 - 8980783
AN - SCOPUS:0031026256
SN - 0066-4804
VL - 41
SP - 204
EP - 211
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 1
ER -